Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | CASP1 | P29466 | 16/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10887551 | 0.86 | SMN1; SMN2 (0.45) | SMN1; SMN2CASP1ALDH1A1 | |
| SCHEMBL2404413 | 0.86 | CASP1 (0.46) | SMN1; SMN2CASP1ALDH1A1 | |
| SCHEMBL16289609 | 0.80 | SMN1; SMN2 (0.46) | SMN1; SMN2CASP1ALDH1A1 | |
| SCHEMBL16289607 | 0.80 | SMN1; SMN2 (0.46) | SMN1; SMN2CASP1ALDH1A1 | |
| SCHEMBL29624611 | 0.80 | CASP1 (0.46) | SMN1; SMN2CASP1ALDH1A1 | |
| SCHEMBL13118364 | 0.80 | CASP1 (0.46) | SMN1; SMN2CASP1ALDH1A1 | |
| SCHEMBL7117245 | 0.79 | SMN1; SMN2 (0.41) | SMN1; SMN2ALDH1A1 | |
| SCHEMBL7117253 | 0.79 | SMN1; SMN2 (0.41) | SMN1; SMN2ALDH1A1 | |
| SCHEMBL29263913 | 0.78 | CASP1 (0.41) | SMN1; SMN2CASP1ALDH1A1 | |
| SCHEMBL21978269 | 0.78 | CASP1 (0.47) | CASP1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7820838-B2 | Method for total synthesis of ecteinascidins and intermediate compounds thereof | JAPAN SCIENCE AND TECHNOLOGY AGENCY (JP) | 2010-10-26 | — | — | US | disclosed |
| US-7807833-B2 | Method for total synthesis of ecteinascidins and intermediate compounds thereof | JAPAN SCIENCE AND TECHNOLOGY AGENCY (JP) | 2010-10-05 | — | — | US | disclosed |
| US-20090198051-A1 | Method For Total Synthesis Of Ecteinascidins And Intermediate Compounds Thereof | FUKUYAMA TOHRU | 2009-08-06 | — | — | US | disclosed |
| US-20090036673-A1 | Method For Total Synthesis Of Ecteinascidins And Intermediate Compounds Thereof | JAPAN SCIENCE AND TECHNOLOGY AGENCY (JP) | 2009-02-05 | — | — | US | disclosed |
| US-7417145-B2 | Process for total synthesis of ecteinascidins and intermediates therefor | JAPAN SCIENCE AND TECHNOLOGY AGENCY (JP) | 2008-08-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090036673-A1 | Method For Total Synthesis Of Ecteinascidins And Intermediate Compounds Thereof | ERLIN2, ETF1, TXN2 | SMN1; SMN2 2591/4885CASP1 2613/4885ALDH1A1 1620/4885 |
| US-20090198051-A1 | Method For Total Synthesis Of Ecteinascidins And Intermediate Compounds Thereof | ERLIN2, ETF1, TXN2 | SMN1; SMN2 2591/4885CASP1 2613/4885ALDH1A1 1620/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.